Black Diamond Therapeutics, Inc. (BDTX) स्टॉक विश्लेषण

कंपनी का अवलोकन

Black Diamond Therapeutics, Inc. operates as a clinical-stage oncology company dedicated to the discovery and development of MasterKey therapies designed for patients with genetically defined tumors. The firm's primary focus involves the advancement of silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which represents its lead product candidate. This biotechnology entity functions within the Healthcare sector and specifically targets the Biotechnology industry, an environment characterized by high innovation requirements and significant regulatory oversight. The company currently maintains a market capitalization of $147.80M, reports annual revenue of $70.00M, and employs a workforce of 21 individuals. These financial metrics suggest a mid-cap enterprise operating with a lean operational structure, where the revenue figure of $70.00M indicates a established revenue stream despite the relatively small employee base of 21, reflecting high-value intellectual property and potentially outsourced development activities.

वित्तीय स्वास्थ्य

The company reported a revenue of $70.00M over the trailing twelve months, generating a net income of $22.37M and an EBITDA of $20.20M. The substantial gap between the $70.00M revenue and the $22.37M net income reveals a cost structure with minimal operating expenses, resulting in a highly efficient conversion of sales into profit. This financial profile is further evidenced by a free cash flow of $13.03M, which provides the company with significant financial flexibility to fund future research and development initiatives without relying heavily on external capital markets. The margin analysis shows a Gross Margin of 100.0%, indicating that the company sells its products or services with no cost of goods sold, a common trait for early-stage biotech firms selling intellectual property or licensing agreements. Additionally, an Operating Margin of 28.4% and a Profit Margin of 32.0% demonstrate strong operational efficiency and the ability to generate substantial profits relative to sales. In terms of solvency, the company holds cash reserves of $128.65M against total debt of $18.78M, resulting in a Debt to Equity ratio of 16.74. While the Debt to Equity ratio is numerically high, the overwhelming cash position suggests a conservative balance sheet where debt obligations are easily covered by available liquidity. The Current Ratio stands at 8.42, indicating an exceptionally strong short-term liquidity position where current assets significantly exceed current liabilities. Furthermore, the Return on Equity is 22.9% and the Return on Assets is 9.3%, metrics that reveal management's effectiveness in generating returns from shareholder investments and total assets respectively.

मूल्यांकन आकलन

Black Diamond Therapeutics, Inc. carries a P/E Ratio (TTM) of 6.62 and a Forward P/E of -2.50. The discrepancy between the trailing P/E of 6.62 and the negative forward P/E of -2.50 implies that the market expects earnings to decline or turn negative in the upcoming period, likely due to anticipated spending on clinical trials or product development costs before revenue recognition. The Price to Book ratio is 1.31, which indicates that the market values the company at a modest premium over its net asset book value, suggesting investors are paying slightly more than the liquidation value of the firm. Alternative valuation metrics such as the Price to Sales ratio of 2.11 and the EV/EBITDA of 1.88 provide context for the company's valuation relative to its revenue generation and earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-Week High of $4.94 and a 52-Week Low of $1.20, with the current trading price situated within this historical range but requiring precise calculation to determine the exact percentage distance from these extremes based on real-time market data. The Beta value is 3.39, which signifies that the stock's price volatility is more than three times that of the broader market, exposing investors to significant fluctuations in share price relative to general market movements.

Growth & Income

The revenue growth (YoY) and earnings growth (YoY) are listed as N/A in the available data. Consequently, it is not possible to determine whether earnings are growing faster or slower than revenue based on the provided historical growth rates. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. This non-dividend status indicates that the firm retains all of its earnings to reinvest into growth activities, such as advancing its clinical-stage oncology pipeline and expanding its research capabilities. The overall growth and income profile is characterized by a lack of current dividend income and undefined historical growth rates, focusing instead on capital appreciation potential driven by the development of its MasterKey therapies.